These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16171045)

  • 1. [Transdermal system].
    Krankenpfl J; 2005; 43(4-6):94. PubMed ID: 16171045
    [No Abstract]   [Full Text] [Related]  

  • 2. Transdermal oxybutynin (oxytrol) for urinary incontinence.
    Dull P
    Am Fam Physician; 2004 Dec; 70(12):2351-2. PubMed ID: 15617300
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cutaneous administration rather than swallowing].
    Schubert-Zsilavecz M
    Krankenpfl J; 2005; 43(7-10):186. PubMed ID: 16515258
    [No Abstract]   [Full Text] [Related]  

  • 4. Transdermal oxybutynin: sticking to the facts.
    Cartwright R; Cardozo L
    Eur Urol; 2007 Apr; 51(4):907-14; discussion 914. PubMed ID: 17157979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in anticholinergic therapy delivery systems.
    Davila GW
    Geriatrics; 2002 May; 57 Suppl 1():29-34. PubMed ID: 12040601
    [No Abstract]   [Full Text] [Related]  

  • 6. Transdermal oxybutynin. A viewpoint by Michael Chancellor.
    Chancellor M
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964893
    [No Abstract]   [Full Text] [Related]  

  • 7. Transdermal oxybutynin. A viewpoint by Adrian Wagg.
    Wagg A
    Drugs Aging; 2003; 20(11):865-6. PubMed ID: 12964894
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary incontinence: oxybutynin topical gel for overactive bladder.
    Chapple CR
    Nat Rev Urol; 2009 Jul; 6(7):351-2. PubMed ID: 19578347
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Rufus Cartwright and Linda Cardozo. Transdermal oxybutynin: sticking to the facts. Eur urol 2007;51:907-14.
    Cornel EB
    Eur Urol; 2007 Jul; 52(1):286-7; author reply 287. PubMed ID: 17434252
    [No Abstract]   [Full Text] [Related]  

  • 12. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial.
    Sand PK; Goldberg RP; Dmochowski RR; McIlwain M; Dahl NV
    Am J Obstet Gynecol; 2006 Dec; 195(6):1730-5. PubMed ID: 17132474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical oxybutynin: practicalities of clinical use.
    Guerrero K; Emery S; Owen L; Rowlands M
    J Obstet Gynaecol; 2006 Feb; 26(2):141-3. PubMed ID: 16483973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of Ditropan in the elderly: nursing responsibilities.
    Anderson CL
    Perspectives; 1993; 17(3):11. PubMed ID: 8116314
    [No Abstract]   [Full Text] [Related]  

  • 16. Restoring continence in frail older people living in the community: what factors influence successful treatment outcomes?
    Harari D; Igbedioh C
    Age Ageing; 2009 Mar; 38(2):228-33. PubMed ID: 19106253
    [No Abstract]   [Full Text] [Related]  

  • 17. A double-blind randomized dose-response study comparing daily doses of 5, 10 and 15 mg controlled-release oxybutynin: balancing efficacy with severity of dry mouth.
    Corcos J; Casey R; Patrick A; Andreou C; Miceli PC; Reiz JL; Harsanyi Z; Darke AC;
    BJU Int; 2006 Mar; 97(3):520-7. PubMed ID: 16469019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of transdermal oxybutynin in the treatment of overactive bladder.
    Sahai A; Mallina R; Dowson C; Larner T; Khan MS
    Int J Clin Pract; 2008 Jan; 62(1):167-70. PubMed ID: 18173821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis comparing trials of antimuscarinic medications funded by industry or not.
    Tulikangas PK; Ayers A; O'Sullivan DM
    BJU Int; 2006 Aug; 98(2):377-80. PubMed ID: 16879680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MATRIX study: assessment of health-related quality of life in adults with the use of transdermal oxybutynin.
    Newman DK
    Director; 2008; 16(1):22-5. PubMed ID: 19343871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.